Biotech Analysts Fadia & Lee, along with Dr. Mark Scarupa, Asthma Allergy/Allergy Specialist at the Institute For Asthma & Allergy, discuss Blueprint Medicines’ Ayvakit for Indolent Systemic Mastocytosis (ISM), the updated PIONEER data presented at AAAAI and the potential competitive impact from Cogent Biosciences’ Bezuclastinib on an Analyst/Industry conference call to be held on February 27 at 11:30 am.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BPMC:
- Blueprint Medicines Reports Fourth Quarter and Full Year 2022 Results
- Blueprint Medicines provides 2023 financial guidance
- Blueprint Medicines reports Q4 EPS ($2.65), consensus ($2.65)
- Blueprint Medicines: FDA puts partial clinical hold on the Phase 1/2 VELA trial
- Blueprint Medicines to present results from PIONEER trial of AYVAKIT